Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy
P
Parminder Singh
(Department of Medicine, Mayo Clinic Alix School of Medicine, Phoenix, AZ)
S
Seth P. Lerner
(Department of Urology, Baylor College of Medicine, Houston)
Article Details
Journal
New England Journal of Medicine
Volume / Issue
Vol. 394, Issue 13
Published
April 02, 2026
Pages
1334-1336
ISSN
0028-4793
Publisher
Massachusetts Medical Society
Journal Info
New England Journal of Medicine
Massachusetts Medical Society
ISSN: 0028-4793 Social Sciences
Authors (2)
P
Parminder Singh
Department of Medicine, Mayo Clinic Alix School of Medicine, Phoenix, AZ
S
Seth P. Lerner
Department of Urology, Baylor College of Medicine, Houston
Related Articles from this Journal
Doctor’s Dirty Little Secret — The Cost of Silence
Tara Khan
Aug 2026
10.1056/nejmp2515506
Obstructive Hypertrophic Cardiomyopathy
Julian-Kai Nishizono, Marohito Nakata
Aug 2026
10.1056/nejmicm2603868
T-Cell Engager–Mediated HLA Antibody Depletion before Kidney Transplantation
Martina Schatzl, Katharina A. Mayer et al.
Jul 2026
10.1056/nejmc2603853
Products That Pose Health Risks — Can Litigation Protect Us When Government Fails?
Jerry Avorn
Jul 2026
10.1056/nejmp2604841
Precision Intensification in Metastatic Prostate Cancer
Rana R. McKay
Jul 2026
10.1056/nejme2605582